[44Sc]Sc-PSMA-617在转移性去势抵抗性前列腺癌患者中的生物分布与剂量测定
肾脏为关键器官,吸收剂量3.19E-01 mSv/MBq,50 MBq(治疗计划剂量)对应的有效剂量为1.95 mSv。
要点
- 5例mCRPC患者注射40-62 MBq [44Sc]Sc-PSMA-617后行PET/CT显像。
- 肾脏为关键器官,吸收剂量3.19E-01 mSv/MBq。
- 50 MBq(治疗计划剂量)对应有效剂量1.95 mSv。
研究设计与样本
- 每例患者静脉注射40-62 MBq [44Sc]Sc-PSMA-617,使用Siemens Biograph 2 PET/CT系统采集腹部30分钟列表模式动态PET数据,并在注射后45分钟、2小时和约20小时采集颅顶至大腿中部的静态PET/CT图像。
- 测定肾脏、膀胱、唾液腺、小肠、肝脏、脾脏和全身等源器官的放射性百分比随时间变化,计算骨髓和膀胱内容物的停留时间,并用OLINDA/EXM软件确定源器官停留时间、器官吸收剂量和有效剂量。
主要发现
- 肾脏、肝脏、脾脏、小肠、膀胱和唾液腺及转移灶可见生理性示踪剂摄取。
- 肾脏吸收剂量最高,为3.19E-01 mSv/MBq,为关键器官;其次为膀胱壁2.24E-01 mSv/MBq、脾脏1.85E-01 mSv/MBq、唾液腺1.11E-01 mSv/MBq和肝脏1.07E-01 mSv/MBq。
- 红骨髓剂量为3.31E-02 mSv/MBq。
- 平均有效剂量为3.89E-02 mSv/MBq;由50 MBq(治疗计划剂量)[44Sc]Sc-PSMA-617估算的有效剂量为1.95 mSv。
关键数值与推荐
- 肾脏吸收剂量3.19E-01 mSv/MBq为最高,被列为关键器官。
- 膀胱壁吸收剂量2.24E-01 mSv/MBq,脾脏1.85E-01 mSv/MBq,唾液腺1.11E-01 mSv/MBq,肝脏1.07E-01 mSv/MBq。
- 红骨髓剂量3.31E-02 mSv/MBq。
- 平均有效剂量3.89E-02 mSv/MBq;50 MBq(治疗计划剂量)对应有效剂量1.95 mSv。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: [Sc]Sc-PSMA-617 with 3.9-hour half-life, in vitro and in vivo characteristics similar to [Lu]Lu-PSMA-617 and possibility of delayed imaging after 24 hours or later, implies it to be advantageous than [ Ga]Ga-PSMA-617 for pretherapeutic dosimetric assessment for [Lu]Lu-PSMA-617 in metastatic castration-resistant prostate carcinoma (mCRPC) patients. In this study, we investigated biodistribution and radiation exposure to normal organs with [Sc]Sc-PSMA-617 in mCRPC patients. METHODS: Five mCRPC patients (mean age, 69 years) enrolled for [Lu]Lu-PSMA-617 therapy were injected with 40-62 MBq [Sc]Sc-PSMA-617 intravenously; Siemens Biograph 2 PET/CT system was used to acquire dynamic PET data (30 minutes) in list mode over the abdomen, followed by the collection of static PET/CT images (skull to mid-thigh) at 45 minutes, 2 and approximately 20 hours postinjection. Time-dependent changes in percentage activity in source organs (kidneys, bladder, salivary glands, small intestine, liver, spleen, and whole body) were determined. Bone marrow and urinary bladder contents residence time were also calculated. Source organs residence time, organ-absorbed doses, and effective doses were determined using OLINDA/EXM software. RESULTS: Physiological tracer uptake was seen in kidneys, liver, spleen, small intestine, urinary bladder, and salivary glands and in metastases. Kidneys with highest radiation absorbed dose of 3.19E-01 mSv/MBq were the critical organs, followed by urinary bladder wall (2.24E-01 mSv/MBq, spleen [1.85E-01], salivary glands [1.11E-01], and liver [1.07E-01] mSv/MBq). Red marrow dose was found to be 3.31E-02 mSv/MBq. The mean effective dose of 3.89E-02 mSv/MBq and effective dose of 1.95 mSv was estimated from 50 MBq (treatment planning dose) of [Sc]Sc-PSMA-617. CONCLUSIONS: [Sc]Sc-PSMA-617 is found to be a very promising radiopharmaceutical that can be used for pre [Lu]Lu-PSMA-617 therapeutic dosimetric assessment.
引用
- Khawar A, Eppard E, Sinnes JP, et al. [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma. Clin Nucl Med. 2018. PMID: 29485430. doi:10.1097/RLU.0000000000002003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。